Takeda Patient Support CoPay Assistance Program
Savings card from Takeda
Recombinate’s maker has a savings program. Its page doesn’t list a dollar amount.
From the maker’s site, checked November 2, 2026. Check the maker’s page for who can use it.
How to pay the least
Ask for the cash price
Recombinate
Recombinate is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold.
- Ask your pharmacy for Recombinate’s cash price, and one or two other pharmacies too.
Compare every option
Question
Brand nameRecombinate
Authorized genericantihemophilic factor recombinant
Regular genericantihemophilic factor recombinant
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldAsk the pharmacy
Same as Recombinate?
The original
–
–
Details for each option
Details for
Brand nameThe maker’s card
Authorized genericNot sold
There isn’t one. An authorized generic is Recombinate itself, from the same company, sold without the brand name, and usually for less. For now Recombinate is the only choice; its maker’s savings card can lower what you pay.
Regular genericNot sold
Recombinate is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.
What it’s used for
What the FDA label says
The use of RECOMBINATE [Antihemophilic Factor (Recombinant)] is indicated in hemophilia A (classical hemophilia) for the prevention and control of hemorrhagic episodes.2 RECOMBINATE is also indicated in the perioperative management of patients with hemophilia A (classical hemophilia).
RECOMBINATE can be of therapeutic value in patients with acquired Factor VIII inhibitors not exceeding 10 Bethesda Units per mL.3 In clinical studies with RECOMBINATE, patients with inhibitors who were entered into the previously treated patient trial and those previously untreated children who have developed inhibitor activity on study, showed clinical hemostatic response when the titer of inhibitor was less than 10 Bethesda Units per mL. However, in such uses, the dosage of RECOMBINATE should be controlled by frequent laboratory determinations of circulating Factor VIII levels as well as the clinical status of the patient.
RECOMBINATE is not indicated in von Willebrand's disease.
Source: the FDA label for Recombinate (Takeda Pharmaceuticals America, Inc.), April 3, 2025. Full label on DailyMed
Good to know
- “Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Check the maker’s page for who can use it.
- Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to your pharmacy.
- Don’t stop or change a medicine without talking to your pharmacist or prescriber.
Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/recombinate/